Loading market dashboard
VanEck Pharmaceutical ETF
PPHFinancial ServicesNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Launched on December 20, 2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story.
VanEck Pharmaceutical ETF offers a concentrated portfolio focused exclusively on drug manufacturers. iShares Global Healthcare ETF provides broader diversification across more than 100 companies in the global medical sector.
The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every healthcare benchmark anyway.
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on June 23, 2005.
When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on December 20, 2011.
VanEck Pharmaceutical ETF (NYSEARCA:PPH) exists to give investors broad exposure to the global pharmaceutical industry without the binary risk of betting on a single drug pipeline.
